Marinomed announces the appointment of Dr. Cornelia Kutzer as Chief Business Officer
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today announced that Dr. Cornelia Kutzer has been appointed as Chief Business Officer (CBO) of the company. As CBO, Dr. Kutzer will be responsible for further expanding Marinomed’s network of strategic partnerships both for product development and distribution in the therapeutic areas infectious diseases and immunology with an emphasis on ophthalmological indications.
“As we increase our efforts to realize the full potential of our product portfolio, we are delighted to now have such a successful and experienced management executive on board to optimize our business development activities,” Dr. Andreas Grassauer, CEO of Marinomed, said. “With her broad commercial expertise and impressive track record including high-value transactions, she will further advance Marinomed’s partnering strategy and will be an important part of our leadership team.”
Dr. Cornelia Kutzer, CBO of Marinomed, added: “It is a great opportunity to join Marinomed at this exciting stage of the company’s development. Marinomed is working on an interesting pipeline of new therapeutics to improve the treatment of a range of diseases. This also includes indications with a high unmet medical need, such as autoimmune gastritis. I am looking forward to my new role at Marinomed and to leveraging my experience to support Marinomed’s future strategic growth.”
Dr. Kutzer‘s experience covers more than 20 years in the pharmaceutical industry in strategic planning, marketing, sales, and business development across a range of indications, including vaccines for infectious and chronic diseases. Most recently, she was CBO at AFFiRiS AG, where she was responsible for partnering efforts including a successful asset deal valued over $50 million. As a consultant, she supported various clients during the ongoing COVID-19 pandemic in the global launch of their vaccines. Previously, she held positions in global marketing at Pfizer and Baxter as Senior Director Vaccines. Dr. Kutzer holds a PhD in pharmacology and toxicology from the Ludwig-Maximilians-Universität München, Germany, where she also completed her diploma in chemistry, and a postgraduate degree in business administration from the Technical University Munich.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian science-based biotech company with globally marketed therapeutics. Marinomed focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv® technology increases the solubility and bioavailability of compounds that are hardly soluble in aqueous formulations. Under the brand Solv4U, Marinomed provides formulation development based on the Marinosolv® technology for external partners. The Carragelose® platform comprises innovative patentprotected products targeting viral infections of the respiratory tract and may also reduce the risk of an infection with SARS-CoV-2. Carragelose® is used as a virus blocker in nasal sprays, throat sprays, and lozenges, which are sold via international partners in over 40 countries. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. The company is based in Korneuburg, Austria, and listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information is available at https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
Lucia Mayr-Harting, PR
Hovengasse 25,
2100 Korneuburg, Austria
T +43 2262 90300 158
Epr@marinomed.com
http://www.marinomed.com